Translating Drug Ideas into Drug Treatments
Although more than 10,000 human diseases are known, only 500 FDA-approved families of drugs are available for doctors to prescribe to patients. Moreover, a mere 25-30 new drugs are approved every year. This situation is largely the result of the difficulty in academia of translating lab discoveries into actual, working drugs. Tel Aviv University believes that Israeli academia can bridge this translational gap—and expand the arsenal of drugs available to doctors.
Against this backdrop, TAU has established the Translational Medicine Initiative. The goal is to revitalize the drug development sphere by identifying potential “golden eggs” at TAU’s biomedical research labs. Drawing on TAU’s drug discovery facilities and expertise, and its links with major hospitals, it aims to fast-track these breakthroughs into viable treatment candidates and then to clinical trials. The Translational Medicine Initiative unites the University’s top researchers from across the campus to conduct collaborative research. With this infrastructure in place, TAU is expected to join the ranks of Harvard, Stanford and NYU—institutions that have already adopted this revolutionary approach to drug research with successful, measurable results.
Supporting Translational Medicine will appeal to donors who wish to propel TAU to the forefront of a medical revolution with the potential to ease suffering and save lives.
Naming Opportunities – Translational Medicine
- Translational Medicine Initiative
- Translational Oncology Research Fund FUNDED
- Translational Medicine Graduate Fellowship Fund
- Translational Medicine Parkinson’s Research Fund
- Translational Medicine Alzheimer’s Research Fund
- Translational Medicine Diabetes Research Fund
- Translational Medicine Rare Diseases Research Fund
To support or receive more information about one of these projects, please contact your local TAU Friends Association or TAU’s Development and Public Affairs Division at +972-3-640-8249 or email@example.com.